1 Vitamin D deficiency as risk factor for severe COVID-19: a convergence of two pandemics

2

3

4 De Smet D. (MD) ¹, De Smet K. (MD) ², Herroelen P. (MSc.) ¹, Gryspeerdt S. (MD) ² and Martens G.A.
5 (MD, PhD) ^{1,3}

6 ¹ AZ Delta Medical Laboratories and ² Department of Radiology, AZ Delta General Hospital, Roeselare,
7 Belgium ³ VUB Metabolomics Platform, Brussels Free University

8

9 Corresponding author: Geert A. Martens, AZ Delta Medical Laboratories, AZ Delta General Hospital,

10 Deltalaan 1, 8800 Roeselare. ORCID <https://orcid.org/0000-0003-1208-6289> Tel: +32 51 23 71 96

11 Email: geert.martens@azdelta.be

12

13

14

15

16 Word count body: 2365

17 Word count abstract: 249

18

19

20

21 medRxiv doi: <https://doi.org/10.1101/2020.05.01.20079376>

22 **Revised version 2, May 15, 2020**

23

24

25 **Trial registration:** Clinical Trial Number IRB B1172020000009

26

28 SUMMARY BOX

29 What is already known on this topic

30 Vitamin D deficiency increases the incidence and severity of respiratory viral infections by
 31 exacerbation of pro-inflammatory immune responses. Lung damage in COVID-19 involves excessive
 32 inflammation and cytokine release. With more than 1 billion people worldwide affected by vitamin D
 33 deficiency the world might now face a convergence of two pandemics. Data are emerging that
 34 variations in vitamin D deficiency rates across ethnic and demographic subgroups are correlated to
 35 severity of SARS-CoV-2 infections.

37 What this study adds

38 Our data reveal that more than 40% of the adult population in a wealthy European country is vitamin
 39 D deficient. We show that vitamin D deficiency is correlated with the risk for hospitalization for
 40 COVID-19 pneumonia and predisposes to more advanced radiological disease stages. Specifically,
 41 men were at risk. This correlation was not confounded by vitamin D-impacted morbidities such as
 42 coronary artery disease, diabetes and chronic lung disease. Our findings support a causal relation
 43 between vitamin D deficiency and severe COVID-19 and call for vitamin D supplementation as safe,
 44 widely available and inexpensive mitigation strategy.

45

46

47

48 **Structured abstract**

49 **Context.** Through its immunological functions, vitamin D attenuates inflammatory responses to
50 respiratory viruses. Vitamin D deficiency might be a highly prevalent risk factor for severe SARS-CoV-
51 2 infections.

52 **Objective.** To investigate the level of vitamin D deficiency in West Flanders, Belgium and its
53 correlation to severity of COVID-19 as staged by CT

54 **Design.** Retrospective observational study

55 Setting. Central network hospital

56 **Participants.** 186 SARS-CoV-2-infected patients hospitalized from March 1, 2020 to April 7, 2020

57 **Main outcome measure.** Analysis of 25(OH)D in COVID-19 patients versus season/age/sex-matched
58 diseased controls

59 **Results.** The rate of vitamin D deficiency (25(OH)D<20 ng/mL) in West Flanders varies with age, sex
60 and season but is overall very high (39.9%) based on analysis of 16274 control samples. We
61 measured 25(OH)D levels in 186 COVID-19 patients (109 males (median age 68 years, IQR 53-79) and
62 77 females (median age 71 years, IQR 65-74)) and 2717 age/season-matched controls (999 males
63 (median age 69 years, IQR 53-81) and 1718 females (median age 68 years, IQR 43-83)). COVID-19
64 patients showed lower median 25(OH)D (18.6 ng/mL, IQR 12.6-25.3, versus 21.5 ng/mL, IQR 13.9-
65 30.8; P=0.0016) and higher vitamin D deficiency rates (58.6% versus 45.2%, P=0.0005). Surprisingly,
66 this difference was restricted to male COVID-19 patients who had markedly higher deficiency rates
67 than male controls (67.0% versus 49.2%, P=0.0006) that increased with advancing radiological stage
68 and were not confounded vitamin D-impacted comorbidities.

69 **Conclusions:** vitamin D deficiency is a prevalent risk factor for severe COVID-19. Vitamin D
70 supplementation might be an inexpensive and safe mitigation for the SARS-CoV-2 pandemic.

71

72 Introduction

73 In severe SARS-CoV-2 infections excessive activity of pro-inflammatory immune cells contributes to
 74 alveolar and endothelial damage triggering a vicious cycle that evolves towards severe COVID-19 ^{1,2}.
 75 Beside its role in calcium metabolism, 1,25-dihydroxyvitamin D (25(OH)D) is a pleiotropic regulator of
 76 the immune system ^{3,4}. It stimulates the expression of cathelicidins and beta-defensin in respiratory
 77 epithelia as barrier to pathogen invasion ^{5,6}. It acts as a pro-tolerogenic cytokine dampening
 78 excessive inflammation by inhibiting neutrophils and switching Th1 CD4 T cells and M1-polarized
 79 macrophages towards a type II immunity. Vitamin D deficiency increases the severity of respiratory
 80 virus infections ^{7,8} and contributes to variations in their incidence across seasons, age groups,
 81 socioeconomic status and geographies. Data are emerging that vitamin D deficiency is more
 82 prevalent in patients with severe COVID-19 pneumonia requiring intensive care ⁹. More than a billion
 83 people worldwide are vitamin D deficient ¹⁰ with variations between sexes, ethnicities, social groups
 84 and geographies that appear to correlate with differences in incidence and outcome of COVID-19
 85 lung disease based on modeling of large data sets ¹¹⁻¹³. Here we provide a first field validation of
 86 these models. We provide a detailed view on the surprisingly high prevalence of vitamin D deficiency
 87 in a wealthy European region, the province of West Flanders, Belgium. We investigated the
 88 correlation of serum 25-hydroxyvitamin D (25(OH)D) level to the risk to be hospitalized for severe
 89 COVID-19 pneumonia, the radiological disease stage as proxy for immunological stage and its
 90 possible confounding by vitamin D-impacted comorbidities, in cohort of 186 consecutive patients
 91 hospitalized for severe SARS-CoV-2 infection in a large Belgian network hospital.

93 Methods

94 **Patients** This is a retrospective observational study on 186 consecutive patients hospitalized from
 95 March 1, 2020 to April 7, 2020 for COVID-19 pneumonia at AZ Delta General Hospital in Roeselare,
 96 Belgium (demographics in Table 2). 25(OH)D levels in COVID-19 patients were compared to an age-
 97 and season-matched diseased control population, consisting of 2717 consecutive unselected patients

sampld from March 1, 2019 to April 30, 2019. The prevalence and age/sex/seasonal-distribution of vitamin D status in the general population was derived from all 25(OH)D measurements from January 1, 2019 to December 31, 2019 on 16274 consecutive, unselected and unique patient samples (Table 1). This study was approved by the AZ Delta ethical committee (Clinical Trial Number IRB B1172020000009) with a waiver of informed consent from study participants considering the study is based on secondary analysis of existing data.

Procedures: Chest CT On admission all COVID-19 patients received a chest CT (detailed CT scanning protocol in Supplementary Information) to determine the disease stage by consensus evaluation of the predominant radiological presentation: ground-glass opacities (early stage, 0-4 days, “stage 1”), crazy paving pattern (progressive stage, 5-8 days, “stage 2”), (3) consolidation (peak stage, 10-13 days, “stage 3”) ¹⁴. **Analysis of comorbidities:** prevalence of diabetes was registered by anamnesis and review of electronic patient records. Chronic lung disease (emphysema, fibrosis, bronchiectasis) and coronary artery disease (coronary artery calcification scoring) were objectified by chest CT. **Laboratory analyses:** all serum 25(OH)D measurements in this study were done in a central lab by the exact same method using Elecsys® vitamin D total II (Roche, Switzerland) traced to the official reference ID-LC-MS/MS (Ghent University). SARS-CoV-2 infection was confirmed in all COVID-19 patients by PCR for E/N/RdRP genes (Allplex™ 2019-nCoV assay, Seegene, Seoul, Korea) on nasopharyngeal swabs.

Statistical analysis Data (not normally distributed) are expressed as medians (IQR) and Mann-Whitney test was used to test statistical differences between groups. Proportions for categorical variables were compared using chi-squared test. Spearman’s rank correlation was used to identify correlations between 25(OH)D and comorbidities as confounding factors (r_s , 95% CI). Statistical analyses were performed using MedCalc (version 12.2.1, Mariakerke, Belgium) and considered significant if P value was less than .05.

Results

Epidemiology and distribution of vitamin D deficiency in the general population The prevalence and distribution of vitamin D deficiency the general population in the province of West Flanders, Belgium, was derived from 25(OH)D measurements in 16274 consecutive, unselected and unique patient sampled from January 1, 2019 to December 31, 2019. Table 1 summarizes the demographics and distributions according to sex, age and season and lists relevant statistical differences. Males had lower median 25(OH)D than females (22.3 ng/mL, IQR 14.9-31.3 versus 23.7 ng/mL, IQR 15.6-33.1, $P<0.0001$) and higher rates of vitamin D deficiency (42.0% versus 38.6%, $P<0.0001$) (Fig. 1A). With the exception of the very young (<10 years), vitamin D deficiency was endemic in all age groups (Fig. 1B, Table 1). Men and women above 18 years showed lower median 25(OH)D levels and higher vitamin D deficiency rates than individuals of 18 years or younger ($P<0.05$). As expected, 25(OH)D levels were lower in winter and spring than in summer ($P<0.0001$) and fall ($P<0.05$) (Fig. 1C). Above the age of 30 years more than 40% of the population was vitamin D-deficient, with men consistently more ($P<0.05$) affected than women (Fig.1D) and in all seasons except summer (Fig. 1E). The time frame of peak SARS-CoV-2 infection in our population thus coincided with the time frame of lowest 25(OH)D levels and highest rates of vitamin D deficiency, with men (48.6%) markedly more affected than females (42.5%, $P<0.05$).

Demographics and vitamin D status of COVID-19 patients. 186 patients with PCR-confirmed SARS-CoV-2 infection were admitted to the hospital from March 1, 2020 to April 7, 2020 for COVID-19 pneumonia: 109 males (median age 68 years, IQR 53-79 years) and 77 females (median age 71 years, IQR 65-74 years). 25(OH)D in COVID-19 patients was compared a control group of 2717 patients with similar age distribution, sampled in March and April, 2019. COVID-19 patients had an even lower median 25(OH)D on admission (18.6 ng/mL, IQR 12.6-25.3) than controls (21.5 ng/mL, IQR 13.9-20.8, $P=0.0016$) and a markedly higher percentage of vitamin D deficiency (defined as 25(OH)D <

20ng/mL): 58.6% versus 45.2% ($P=0.0005$) (Table 2). Considering the male preponderance in COVID-19 patients (59%) but underrepresentation in controls (37%), we then stratified 25(OH)D for sex (Fig.2A-C and Table 2). Remarkably, we observed a sexual dimorphism. Female COVID-19 patients were not more vitamin D deficient than female controls (46.8% versus 42.8%, $P=0.5646$, Fig.2B). Control males showed higher vitamin D deficiency rates than control females (49.2% versus 42.8%, $P<0.0001$ Fig.2A). In male COVID-19 patients, vitamin D deficiency was even more profound (Fig.2C), with lower median 25(OH)D (17.6 ng/mL, IQR 12.7-24.0 versus 20.3 ng/mL, IQR 13.7-28.3, $P=0.0234$) and a markedly higher deficiency rate (67.0% versus 49.2%, $P=0.0006$) than male controls.

Correlation between vitamin D status and disease stage Patients were screened by CT to determine the temporal phase of COVID-19 lung disease and classified based on the predominant radiological lesion (Fig.2D-F) as early stage 1 (ground-glass opacities), progressive stage 2 (crazy paving pattern) or peak stage 3 (consolidation). These stages are considered as proxy for the immunological phase of COVID-19 with an early phase of active viral replication in lower airways (stage 1), progressive recruitment of pro-inflammatory cells to the lung interstitial space (stage 2), ending in diffuse alveolar damage and fibrosis (stage 3). 24.7%, 29.6% and 45.7% of patients presented in stage 1, 2 and 3, respectively with similar distribution in males and females (Table 2). Analysis of 25(OH)D across radiological disease stages (Fig.2G-H, Table 2) strengthened the correlation: male COVID-19 patients showed progressively lower median 25(OH)D with advancing stage, resulting in vitamin D deficiency rates increasing from 55.2% in stage 1, 66.7% in stage 2 to 74.0% in stage 3 ($P=0.0010$). No such stage-dependent 25(OH)D variations were seen in female COVID-19 patients.

Analysis of possible confounders by vitamin D-impacted comorbidities The higher rates of vitamin D deficiency in COVID-19 patients might reflect a causal relation or be no more than a marker of poor general health or nutritional status predisposing to severe COVID-19. To identify possible confounders, we compared the prevalence of known vitamin D-impacted comorbidities such as

chronic obstructive lung disease^{15,16}, coronary artery disease and diabetes, in male versus female and in vitamin D-deficient versus -replete COVID-19 patients. Prevalence of chronic lung disease, coronary artery disease and diabetes in all COVID-19 patients were 15.1%, 59.1% and 14.0%, respectively, with no differences across COVID-19 disease stages (Table 2). The high prevalence of coronary artery disease in COVID-19 patients was strongly correlated to patients' age ($r_s = 0.655$, 95% CI 0.565-0.730, $P < 0.0001$). Male COVID-19 patients showed similar prevalence of diabetes and coronary artery disease and a tendency towards more chronic lung diseases, that attained significance only in male COVID-19 stage 1 patients. The latter difference was, however, not related to differences in vitamin D status: male and female COVID-19 patients with normal (25(OH)D ≥ 20 ng/mL) or deficient vitamin D status showed comparable prevalence of chronic lung disease, coronary artery disease and diabetes (Table 3), indicating that the correlation between vitamin D deficiency and the risk for severe COVID-19 was not confounded by any of these comorbidities.

Discussion

This study is one of several rapidly emerging reports that correlate vitamin D deficiency to the risk for severe presentations of COVID-19 lung disease. It is compatible with a recent study that correlated severe vitamin D deficiency in the Philippines's population with COVID-19 disease burden and poor outcome⁹. Our study is the first to show that more profound vitamin D deficiency predisposes to more advanced radiological stages as proxy for the severity of the inflammatory process of COVID-19 pneumonia. It also describes a remarkable sexual dimorphism, not directly explained by sex differences in overall vitamin D status in our population. This study also highlights vitamin D deficiency as a neglected health issue, even in a wealthy population with access to good nutrition and healthcare: with exception of the very young, more than 40% of our control population have 25(OH)D levels below 20 ng/mL, a widely used threshold for adequate bone health. It can be assumed that these numbers are representative for the total Belgian population that showed much higher all-cause excess mortality during the SARS-CoV-2 peak infection phase than neighboring

countries according to the European Mortality Monitoring project¹⁷ despite largely sufficient hospital and ICU capacity. Our data thus represent a first field validation of a recent global epidemiological analysis that clearly correlated the overall incidence and mortality of COVID-19 to geographical latitude, nations' nutritional status and the associated known impact on vitamin D deficiency as proposed causal factor¹³.

Vitamin D deficiency might be cause or consequence of severe COVID-19 lung disease. It might also be simply a surrogate marker for an underlying confounding comorbidity or general indicator of poor nutrition and ill health. Chronic obstructive pulmonary disease and asthma have been shown to alter 25(OH) metabolism or sequestration^{15,16} with lower increments in circulating 25(OH)D status after controlled repletion. Vitamin D deficiency has also been correlated¹⁸ to known COVID-19 risk factors such as hypertension and diabetes. Our analysis of comorbidities strongly argue against such confounding effect: vitamin D deficiency was strongly correlated to the risk of advanced COVID-19, specifically in males, but vitamin D deficient COVID-19 patients did not show higher prevalence of known vitamin D-impacted diseases such as diabetes, coronary artery disease and chronic lung disease. Another possible confounder is increased catabolism of circulating 25(OH)D in COVID-19 patients, attributed to extrarenal CYP27B1 activity and VDR expressed by the expanded repertoire of immune cells. In a USA population survey, subjects with CRP>5 mg/L showed 1.6 ng/L lower median 25(OH)D²⁰. However, the stable 25(OH)D levels in female COVID-19 patients across all stages of the disease argue against such effect. Combined, our data thus support a causal role of vitamin D deficiency, in line with a recent modeling study using causal interference analysis of global COVID-19 incidence and mortality data¹³.

A substantial body of evidence explains a causal pathophysiological role of vitamin D in the severity of respiratory viral infections. The immunological response to SARS-CoV-2 shows many similarities to the response to SARS-CoV²¹: in individuals with delayed type I/III interferon response and delayed viral clearance, progressive recruitment of neutrophils and pro-inflammatory Th1/M1-polarized immune cells contribute to endothelial and alveolar cell death and in some patients trigger a

cytokine storm¹ that enhances diffuse alveolar damage. Severe COVID-19 can thus be conceptualized as an unbalance between pro-inflammatory type I immune response required for viral clearance and tolerogenic type II response required for repair^{1,2,21}. Vitamin D modulates the immunological response to respiratory viruses at various phases: in the early phase of infection it limits viral entry and replication by boosting cathelicidins/defensins expression in respiratory epithelia⁵. Later on it exerts a tolerogenic effect by directly mediating IL-4/IL-13-dependent polarization towards M2-macrophages and Th2 CD4 T cells⁶. The mammalian immune system shows conserved estrogen/androgen-dependent sexual dimorphism²². SARS-CoV-infected female mice show lower viral replication, lower recruitment of inflammatory monocytes and neutrophils to the lungs and less alveolar and endothelial cell death²³. If vitamin D deficiency favors a pro-inflammatory balance, the higher rates of vitamin D deficiency in male humans might thus act in concert with estrogen/androgen-dependent immune differences and contribute to higher incidence and severity in male COVID-19 patients.

Several randomized controlled interventional trials with vitamin D supplementation for bone health or to reduce mortality in cardiovascular disease and cancer gave mixed or negative results, entailing a sense of indifference from the medical community towards the value of vitamin D monitoring and supplementation. An overlooked issue, however, was that many of those interventional trials showed inappropriate design by targeting populations with no prior vitamin D deficiency, and were not guided by actual 25(OH)D measurements²⁴. A prior meta-analysis indicated that vitamin D supplementation reduces the incidence and severity of acute respiratory infections but only in those patients with a deficient vitamin D level at the start as measured by 25(OH)D²⁵.

In conclusion, our study shows a strong correlation between vitamin D deficiency and severe COVID-19 lung disease that is not explained by confounding comorbidities. In light of the established immunological functions of vitamin D, it is compatible with a causal role of vitamin D deficiency that can explain variations in disease burden of COVID-19 across geographies, skin pigment types (African/Latino), body mass (obese), socioeconomic status (poor) and lifestyle (institutionalized

people). Given the global prevalence of vitamin D deficiency, our data thus argue for vitamin D supplementation as inexpensive, safe and readily available mitigation of the syndemic convergence of two pandemics.

Competing interest and funding declaration

The authors declare no conflict of interest. The authors received no funding for this study.

Contributor and guarantor information

D.D.S., K.D.S and G.M. were responsible for planning and design of the study. Statistical analysis was done by D.D.S. P.H. was responsible for laboratory analyses. S.G. and K.D.S. were responsible for CT and structured reporting of radiological data. All authors contributed to the manuscript preparation, read and approved it. G.M. was responsible for preparing the manuscript and is guarantor of the study. The guarantor affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. The authors declare that they will share anonymized source data of this study upon written request to the guarantor.

References

1. Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. *J Clin Invest*. 2020.
2. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet*. 2020;395(10229):1033-1034.
3. Chirumbolo S, Bjorklund G, Sboarina A, Vella A. The Role of Vitamin D in the Immune System as a Pro-survival Molecule. *Clin Ther*. 2017;39(5):894-916.
4. Cantorna MT, Yu S, Bruce D. The paradoxical effects of vitamin D on type 1 mediated immunity. *Mol Aspects Med*. 2008;29(6):369-375.
5. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science*. 2006;311(5768):1770-1773.
6. Cantorna MT. Vitamin D and Lung Infection. *Infect Immun*. 2016;84(11):3094-3096.
7. Zdrenghea MT, Makrinioti H, Bagacean C, Bush A, Johnston SL, Stanciu LA. Vitamin D modulation of innate immune responses to respiratory viral infections. *Rev Med Virol*. 2017;27(1).
8. Greiller CL, Martineau AR. Modulation of the immune response to respiratory viruses by vitamin D. *Nutrients*. 2015;7(6):4240-4270.
9. Alipio N. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-2019). *Preprint available at SSRN: <https://ssrncom/abstract=3571484>*. 2020.
10. Hilger J, Friedel A, Herr R, et al. A systematic review of vitamin D status in populations worldwide. *Br J Nutr*. 2014;111(1):23-45.
11. Khunti KP, M. Is ethnicity linked to incidence or outcomes of covid-19? *BMJ* (369).
12. Alipio N. Vitamin D Supplementation Could Possibly Improve Clinical Outcomes of Patients Infected with Coronavirus-2019 (COVID-19) (April 9, 2020). *Preprint available at SSRN: <http://dxdoiorq/102139/ssrn3571484>*.
13. Davies G, Garami AR, Byers J. Evidence Supports a Causal Model for Vitamin D in COVID-19 Outcomes. *medRxiv 2020050120087965*; doi: <https://doiorg/101101/2020050120087965>.
14. Bernheim A, Mei X, Huang M, et al. Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection. *Radiology*. 2020:200463.
15. Jolliffe DA, Stefanidis C, Wang Z, et al. Vitamin D Metabolism is Dysregulated in Asthma and Chronic Obstructive Pulmonary Disease. *American journal of respiratory and critical care medicine*. 2020.
16. Hiemstra PS, de Jongh RT. Vitamin D Deficiency in Asthma and Chronic Obstructive Pulmonary Disease: A Chicken or Egg Story. *American journal of respiratory and critical care medicine*. 2020.
17. Kanieff M, Rago G, Minelli G, et al. The potential for a concerted system for the rapid monitoring of excess mortality throughout Europe. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin*. 2010;15(43).
18. Gouni-Berthold I, Berthold HK. Vitamin D and vascular disease. *Current vascular pharmacology*. 2020.

19. Mondul AM, Weinstein SJ, Layne TM, Albanes D. Vitamin D and Cancer Risk and Mortality: State of the Science, Gaps, and Challenges. *Epidemiologic reviews*. 2017;39(1):28-48.
20. Haynes BM, Pfeiffer CM, Sternberg MR, Schleicher RL. Selected physiologic variables are weakly to moderately associated with 29 biomarkers of diet and nutrition, NHANES 2003-2006. *J Nutr*. 2013;143(6):1001S-1010S.
21. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. *Semin Immunopathol*. 2017;39(5):529-539.
22. Trigunaite A, Dimo J, Jorgensen TN. Suppressive effects of androgens on the immune system. *Cell Immunol*. 2015;294(2):87-94.
23. Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol*. 2017;198(10):4046-4053.
24. Grant WB, Boucher BJ, Bhattoa HP, Lahore H. Why vitamin D clinical trials should be based on 25-hydroxyvitamin D concentrations. *J Steroid Biochem Mol Biol*. 2018;177:266-269.
25. Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. 2017;356:i6583.

Table legends

Table 1: Sex, age and seasonal variations in 25(OH) levels in the general population as derived from 25(OH)D measurements in 16274 unselected, consecutive and unique diseased control samples. The table lists for the number (percentage) of patients for the indicated groups, median (IQR) age (years), median (IQR) 25(OH)D level (ng/mL) and percentage vitamin D deficiency. Data (not normally distributed) are expressed as medians (25th–75th percentiles), and the Mann-Whitney test was used to test statistical difference between groups. Proportions for categorical variables were compared using chi-squared test. Upper case letters indicate relevant statistical differences detailed in the footnote.

Table 2: Demographic and comorbidity characteristics of diseased controls and COVID-19 patients and 25(OH) levels stratified by sex and radiological COVID-19 disease stage. † Indicates differences with diseased controls for which P values less than .05 were considered statistically significant. ‡ Indicates differences with CT Stage 1 COVID-19 patients for which P values less than .05 were considered statistically significant. § Indicates differences of male versus female comorbidity prevalence for which P values less than .05 were considered statistically significant. Data (not normally distributed) are expressed as medians (25th–75th percentiles), and the Mann-Whitney test was used to test statistical difference between groups. Proportions for categorical variables were compared using chi-squared test. Exact P values listed in Supplementary information.

Table 3: Prevalence of comorbidities within COVID-19 patients stratified for sex and vitamin D deficiency status. Prevalence of the indicated vitamin D-impacted comorbidities are listed for all COVID-19 patients and grouped per sex (absolute number and percentage per subgroup) and compared between patients with or without vitamin D deficiency (25(OH)D < 20 ng/mL). P values calculated by chi-squared testing indicate statistical differences between prevalence of the indicated

367 comorbidity between all, female or male vitamin D deficient versus sufficient COVID-19 patients. †

368 Indicates no statistical differences between males and females for the indicated comorbidity.

369

370

Table 1: Table 1: Sex, age and seasonal variations in 25(OH) levels in the general population

Patient group	n (%)	Age, Median (IQR), y	25-OH-Vit D, Median (IQR), ng/mL	25-OH-Vit D < 20 ng/mL, n (%)
Gender distribution				
All	16274 (100)	64.2 (39.8-81.3)	23.3 (15.3-32.4)	6491 (39.9)
Female	10045 (61.7)	63.3 (37.4-82.0)	23.7 (15.6-33.1)	3875 (38.6)
Male	6229 (38.3)	65.2 (44.5-80.3)	22.3 (14.9-31.3) ^a	2616 (42.0) ^b
Age (year) distribution				
All				
≤ 1	113 (0.7)	0.7 (0.3-0.8)	44.4 (37.3-55.1)	6 (5.3)
1-10	761 (4.7)	5.0 (2.9-7.3)	32.7 (26.0-42.0)	83 (10.9)
10-18	399 (2.5)	13.1 (11.5-15.3)	23.9 (17.4-30.0)	130 (32.6)
18-30	1410 (8.7)	25.8 (22.6-27.9)	22.2 (15.5-30.0) ^{c, d}	600 (42.6) ^{e, f}
30-50	2842 (17.5)	40.1 (34.9-45.5)	22.5 (15.7-30.6) ^{c, d}	1171 (41.2) ^e
50-70	3727 (22.9)	60.1 (55.4-65.1)	23.4 (15.6-32.6) ^c	1467 (39.4) ^e
>70	7022 (43.1)	82.9 (77.5-87.7)	22.3 (13.9-31.9) ^{c, d}	3034 (43.2) ^{e, f}
Female				
≤ 1	49 (0.5)	0.7 (0.4-0.8)	44.8 (38.8-54.6)	4 (8.2)
1-10	360 (3.6)	5.5 (3.2-7.3)	32.9 (25.5-41.7)	33 (9.2)
10-18	240 (2.4)	13.6 (11.5-15.5)	23.3 (17.0-29.9) ^g	83 (34.6) ⁱ
18-30	1088 (10.8)	26.2 (23.1-28.0)	22.4 (15.6-30.1) ^{g, h}	455 (41.8) ^{i, j}
30-50	1862 (18.5)	39.1 (34.3-44.6)	22.9 (15.9-31.6) ^{g, h}	737 (39.6) ⁱ
50-70	2104 (20.9)	59.7 (55.2-64.8)	24.7 (16.5-34.2) ^g	766 (36.4) ^{i, j}
>70	4342 (43.2)	83.6 (78.2-88.1)	23.1 (14.0-32.9) ^{g, h}	1797 (41.4) ⁱ
Male				
≤ 1	64 (1.0)	0.6 (0.3-0.8)	44.3 (37.1-55.7)	2 (3.1)
1-10	401 (6.4)	4.7 (2.6-7.3)	32.1 (26.3-42.0)	50 (12.5)
10-18	159 (2.6)	12.8 (11.4-14.9)	24.5 (18.7-31.1)	47 (29.6)
18-30	322 (5.2)	24.4 (21.2-27.4)	21.6 (14.9-29.1) ^k	145 (45.0) ^m
30-50	980 (15.7)	41.7 (36.4-46.2)	21.8 (15.5-29.3) ^{k, l}	434 (44.3) ^{m, n}
50-70	1623 (26.1)	60.7 (55.6-65.5)	21.9 (14.4-30.7) ^{k, l}	701 (43.2) ^{m, n}
>70	2680 (43.0)	81.9 (76.5-86.7)	21.2 (13.8-30.1) ^{k, l}	1237 (46.2) ^{m, n}
Seasonal distribution				
Winter				
All	3889 (100)	62.5 (37.7-81.4)	21.8 (14.3-31.4) ^o	1740 (44.7) ^q
Female	2448 (62.9)	62.5 (36.1-81.3)	22.6 (14.5-32.4) ^o	1040 (42.5) ^q
Male	1441 (37.1)	62.8 (40.9-79.5)	20.4 (14.1-29.8) ^{o, p}	700 (48.6) ^{q, r}
Spring				
All	4277 (100)	65.8 (40.5-81.6)	22.2 (14.4-31.0) ^o	1832 (42.8) ^q
Female	2563 (59.9)	64.2 (37.3-82.0)	22.4 (14.8-31.6) ^o	1075 (41.9) ^q
Male	1714 (40.1)	67.5 (46.3-81.0)	21.8 (14.0-30.3) ^{o, p}	757 (44.2) ^q
Summer				
All	3619 (100)	63.3 (40.6-81.6)	25.7 (17.0-35.0)	1202 (33.2)
Female	2296 (63.4)	63.6 (38.8-82.5)	25.8 (17.2-35.4)	748 (32.6)
Male	1323 (36.6)	62.9 (43.3-80.1)	25.6 (16.7-34.2)	454 (34.3)
Fall				
All	4489 (100)	64.7 (40.1-80.9)	23.6 (15.9-32.6) ^o	1717 (38.3) ^q

Female	2738 (61.0)	63.1 (37.4-81.3)	24.2 (16.1-33.3) ^o	1012 (37.0) ^q
Male	1751 (39.0)	66.3 (45.7-80.3)	23.0 (15.6-31.3) ^{o,p}	705 (40.3) ^{q,r}

- ^a 25-OH Vitamin D levels were significantly lower ($P < .0001$) in men than in women.
- ^b Prevalence of 25-OH Vitamin D deficiency was significantly higher ($P < .0001$) in men than in women.
- ^c 25-OH Vitamin D levels were significantly lower ($P < .05$) for all individual age groups > 18 years as compared with those aged ≤ 18 years.
- ^d For all individuals aged > 18 years, subgroup 50-70 years showed significantly higher ($P < 0.05$) as compared with the other age groups.
- ^e All age groups > 18 years showed significantly higher ($P < .05$) prevalence of 25-OH Vitamin D deficiency as compared with the individual age groups ≤ 18 years.
- ^f For individuals aged > 18 years, subgroup 50-70 years showed significantly lower ($P < 0.05$) prevalence of 25-OH Vitamin D deficiency than the age groups 18-30 years and > 70 years.
- ^g 25-OH Vitamin D levels were significantly lower ($P < .0001$) for female age groups > 10 years as compared with those aged ≤ 10 years.
- ^h For women aged > 18 years, subgroup 50-70 years showed significantly higher ($P < 0.001$) 25-OH Vitamin D levels as compared with the other age groups.
- ⁱ All female age groups > 10 years showed significantly higher ($P < .001$) prevalence of 25-OH Vitamin D deficiency as compared with the individual age groups ≤ 10 years.
- ^j For women aged > 10 years, subgroups 10-18 years and 50-70 years showed significantly lower ($P < .05$) prevalence of 25-OH Vitamin D deficiency as compared with the other age groups.
- ^k 25-OH Vitamin D levels were significantly lower ($P < .001$) for male age groups > 18 years as compared with those aged ≤ 18 years. Male age groups > 18 years did not show significant mutual differences.
- ^l 25-OH Vitamin D levels were significantly lower ($P < .001$) for male age groups > 30 years as compared with female age groups > 30 years.
- ^m All male age groups > 18 years showed significantly higher ($P < .001$) prevalence of 25-OH Vitamin D deficiency as compared with the individual age groups ≤ 18 years. Male age groups > 18 years did not show significant mutual differences.
- ⁿ Male age groups 30-50 years, 50-70 years and > 70 years showed significantly higher prevalence of 25-OH Vitamin D deficiency as compared with the female age groups (respectively $P < .05$, $P = .0001$ and $P < .0001$).
- ^o For all patients and gender subgroups, 25-OH Vitamin D levels in winter and spring did not differ significantly. Winter-spring 25-OH Vitamin D levels were significantly lower as compared with summer ($P < .0001$) and fall ($P < .05$). 25-OH Vitamin D levels were significantly lower ($P < .0001$) in fall than those measured in summer.
- ^p In all seasons, except for the summer, males have significantly lower 25-OH Vitamin D levels ($P < .05$) as compared with women.
- ^q For all patients and female patients, prevalence of 25-OH Vitamin D deficiency in winter versus spring did not differ significantly. In contrast, male patients showed significantly higher ($P < .05$) prevalence of 25-OH Vitamin D deficiency in winter versus spring. For all patients and gender subgroups, winter-spring prevalence of 25-OH Vitamin D deficiency were significantly higher as compared with summer ($P < .001$) and fall ($P < .05$). 25-OH Vitamin D deficiency was significantly more prevalent ($P < .001$) in fall than in summer.
- ^r In winter and fall, prevalence of 5-OH Vitamin D deficiency was significantly higher ($P < .05$) in men than in women.

Table 2. Demographic and comorbidity characteristics of diseased controls and COVID-19 patients and 25(OH) levels stratified by sex and radiological COVID-19 disease stage

Patient group	Characteristic	Diseased Controls	COVID-19 (all)	COVID-19 (CT Stage 1)	COVID-19 (CT Stage 2)	COVID-19 (CT Stage 3)
All patients	n	2717	186	46	55	85
	Age, median (IQR), y	68 (49-82)	69 (52-80)	74 (53-82)	71 (60-78)	63 (50-80)
	Sex					
	Female, n (%)	1718 (63.2)	77 (41.4) [†]	17 (37.0) [†]	25 (45.5) [†]	35 (41.2) [†]
	Male, n (%)	999 (36.8)	109 (58.6) [†]	29 (63.0) [†]	30 (54.5) [†]	50 (58.8) [†]
	Comorbidity					
	Chronic lung disease, n (%)	n.d.	28 (15.1)	8 (17.4)	9 (16.4)	11 (12.9)
	Coronary artery disease, n (%)	n.d.	110 (59.1)	32 (69.6)	32 (58.2)	46 (54.1)
	Diabetes, n (%)	n.d.	26 (14.0)	9 (19.6)	7 (12.7)	10 (11.8)
	25-OH-Vitamin D					
	Median (IQR), ng/mL	21.5 (13.9-20.8)	18.6 (12.6-25.3) [†]	19.7 (16.2-30.8)	17.6 (12.0-26.0) [†]	16.9 (12.6-23.8) [†]
	≥ 20 ng/mL, n (%)	1490 (54.8)	77 (41.4) [†]	22 (47.8)	23 (41.8)	32 (37.6) [†]
	< 20 ng/mL, n (%)	1227 (45.2)	109 (58.6) [†]	24 (52.2)	32 (58.2)	53 (62.4) [†]
Female patients	n	1718	77	17	25	35
	Age, median (IQR), y	68 (46-83)	71 (65-74)	68 (46-83)	72 (64-76)	66 (49-82)
	Comorbidity					
	Chronic lung disease, n (%)	n.d.	7 (9.1)	0 (0.0) [§]	3 (12.0)	4 (11.4)
	Coronary artery disease, n (%)	n.d.	43 (55.8)	11 (64.7)	13 (52.0)	19 (54.3)
	Diabetes, n (%)	n.d.	11 (14.3)	4 (23.5)	4 (16.0)	3 (8.6)
	25-OH-Vitamin D					
	Median (IQR), ng/mL	22.4 (14.2-32.0)	20.7 (12.4-29.8)	20.7 (10.4-33.0)	20.3 (11.7-27.7)	21.2 (15.1-29.6)
	≥ 20 ng/mL, n (%)	983 (57.2)	41 (53.2)	9 (52.9)	13 (52.0)	19 (54.3)
	< 20 ng/mL, n (%)	735 (42.8)	36 (46.8)	8 (47.1)	12 (48.0)	16 (45.7)
Male patients	n	999	109	29	30	50
	Age, median (IQR), y	69 (53-81)	68 (53-79)	74 (58-81)	71 (59-78)	59 (52-77)
	Comorbidity					
	Chronic lung disease, n (%)	n.d.	21 (19.3)	8 (27.6) [§]	6 (20.0)	7 (14.0)
	Coronary artery disease, n (%)	n.d.	67 (61.5)	21 (72.4)	19 (63.3)	27 (54.0)
	Diabetes, n (%)	n.d.	5 (13.8)	5 (17.2)	3 (10.0)	7 (14.0)
	25-OH-Vitamin D					
	Median (IQR), ng/mL	20.3 (13.7-28.4)	17.6 (12.7-24.0) [†]	19.4 (18.2-29.8)	16.5 (12.1-24.0) [†]	16.0 (12.0-22.1) [†]
	≥ 20 ng/mL, n (%)	507 (50.8)	36 (33.0) [†]	13 (44.8)	10 (33.3)	13 (26.0) [†]
	< 20 ng/mL, n (%)	492 (49.2)	73 (67.0) [†]	16 (55.2)	20 (66.7)	37 (74.0) [†]

[†] Indicates differences with diseased controls for which P values less than .05 were considered statistically significant.

[‡] Indicates differences with CT Stage 1 COVID-19 patients for which P values less than .05 were considered statistically significant.

[§] Indicates differences of male vs female comorbidity prevalence for which P values less than .05 were considered statistically significant.

372

Table 3. Prevalence of comorbidities within COVID-19 patients stratified for sex and vitamin D deficiency status.

Patient group	Comorbidity	25-OH-vitamin D ≥ 20 ng/mL	25-OH-vitamin D < 20 ng/mL	P
All patients (n = 186)	n	77	109	
	Chronic lung disease, n (%)	13 (16.9)	15 (13.8)	.7085
	Coronary artery disease, n (%)	48 (62.3)	62 (56.9)	.5575
	Diabetes, n (%)	11 (14.3)	15 (13.8)	.9063
Female patients (n = 77)	n	41	36	
	Chronic lung disease, n (%)	4 (9.8)	3 (8.3)	.8660
	Coronary artery disease, n (%)	25 (61.0)	18 (50.0)	.4594
	Diabetes, n (%)	7 (17.1)	4 (11.1)	.6714
Male patients (n = 109)	n	36	73	
	Chronic lung disease, n (%)	9 (25.0) [†]	12 (16.4) [†]	.4163
	Coronary artery disease, n (%)	23 (63.9) [†]	44 (60.3) [†]	.8776
	Diabetes, n (%)	4 (11.1) [†]	11 (15.1) [†]	.7838

P values less than .05 were considered statistically significant.

† Additional male to female comparisons for prevalence of comorbidities showed no statistical differences (P > .05).

373

374

375 **Figure 1**
376

378
379 **Figure 1: Prevalence and distribution of vitamin D deficiency in the general population** as derived
380 from 25(OH)D measurements in 16274 unselected, consecutive and unique diseased control samples
381 Box-and-Whisker plots show median (IQR) 25(OH)D levels (ng/mL) grouped by (A) sex, (B) the
382 indicated age groups and (C) Northern hemisphere meteorological seasons. Background color in box
383 plots indicates normal vitamin D status (green, 25(OH)D > 30 ng/mL), vitamin D deficiency (pale red,
384 25(OH)D < 20 ng/mL), severe vitamin D deficiency (darker red, 25(OH)D < 12 ng/mL) and a gray zone
385 (20 ng/mL ≤ 25(OH)D ≤ 30 ng/mL). Lower panels indicate the percentage vitamin D deficiency
386 (25(OH)D < 20 ng/mL) in females (gray bars) and males (black bars) (D) in the indicated age groups
387 (years) and (E) across seasons. Corresponding numbers per group, median (IQR) 25(OH)D, deficiency
388 rates and relevant statistical differences are detailed in Table 1.

389
390

Figure 2

Figure 2: 25(OH)D levels in male and female COVID-19 patients and age/season-matched controls and stratification by COVID-19 disease stage Panels A-C: Box-and-Whisker plots showing median (red line) serum 25(OH) levels and interquartile ranges (green box) in (A) season- and age-matched female (n=1718) versus male (n=999) diseased controls; (B) female COVID-19 patients on admission (n=77) versus female controls; (C) male COVID-19 patients on admission (n=109) versus male controls. Panels D-F: representative images of radiological stages of COVID-19 lung disease with predominantly (D) ground-glass opacities in early stage; (E) crazy paving patterns in progressive stage 2; and (F) consolidation in peak stage 3. Panel G-H: box-and-whisker plots of 25(OH)D in (G) female COVID-19 patients and (H) male COVID-19 patients grouped according to radiological stage. Background color in box plots indicates normal vitamin D status (green, 25(OH)D > 30 ng/mL), vitamin D deficiency (pale red, 25(OH)D < 20 ng/mL), severe vitamin D deficiency (darker red, 25(OH)D < 12 ng/mL) and a gray zone (20 ng/mL ≤ 25(OH)D ≤ 30 ng/mL). P values indicate statistical

407 differences between groups calculated by Mann-Whitney test. Exact P values listed in Supplementary
408 information.